经会阴前列腺穿刺活检诊断前前列腺癌的临床意义。
Detection of clinically significant cancer in the anterior prostate by transperineal biopsy.
机构信息
Department of Urology, Ballarat Health Services, Ballarat Central, Victoria, Australia.
Department of Urology, Ballarat Health Services, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
出版信息
BJU Int. 2020 Sep;126 Suppl 1:33-37. doi: 10.1111/bju.15124. Epub 2020 Aug 4.
OBJECTIVE
To determine the incidence of clinically significant prostate cancer (csPCa) detected exclusively in the anterior prostate using transperineal prostate biopsy.
PATIENTS AND METHODS
Histopathology results of all patients who underwent transperineal prostate biopsy between February 2016 and March 2018 at a single institution were assessed for distribution of cancer within the prostate. Patients with cancer found exclusively in the anterior prostate were then compared to those with any cancer found in the posterior or lateral prostate with International Society of Urological Pathology Grade Group 2-5 cancers being considered csPCa.
RESULTS
A total of 508 patients were included. Overall, 12.0% of the cohort had csPCa detected only in anterior biopsies. When stratified by prostate-specific antigen (PSA) level, 6.6% of men with a PSA level of 4.1-10.0 ng/mL and 8.2% of men with a PSA level of >10.0 ng/mL had csPCa detected in the anterior prostate alone.
CONCLUSION
Transperineal biopsy has the ability to diagnose anteriorly located csPCa that would potentially have been missed by the transrectal approach.
目的
确定经会阴前列腺活检检测到的仅在前叶前列腺中存在的临床显著前列腺癌（csPCa）的发生率。
患者与方法
评估 2016 年 2 月至 2018 年 3 月在一家机构接受经会阴前列腺活检的所有患者的组织病理学结果，以评估前列腺内癌症的分布情况。然后，将仅在前叶前列腺中发现癌症的患者与在后叶或侧叶前列腺中发现任何癌症（国际泌尿病理学会分级分组 2-5 级癌症被认为是 csPCa）的患者进行比较。
结果
共纳入 508 例患者。总体而言，12.0%的患者在前叶活检中仅发现 csPCa。按前列腺特异性抗原（PSA）水平分层，PSA 水平为 4.1-10.0ng/mL 的男性中有 6.6%、PSA 水平>10.0ng/mL 的男性中有 8.2%的患者仅在前叶前列腺中发现 csPCa。
结论
经会阴活检能够诊断出经直肠方法可能遗漏的位于前叶的 csPCa。
Zotero 插件